Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06361758
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-08
Brief Title:
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Organization Data
Organization:
Shanghai Zhongshan Hospital
Class:
OTHER
Study ID:
B2023-3262
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Zhongshan Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Hui-Chuan Sun
Responsible Party Title:
Director
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shanghai Zhongshan Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Sun Yat-sen University | OTHER |
| Eastern Hepatobiliary Surgery Hospital | OTHER |